Protocol Development Co-Chair for Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK 1349572, a novel integrase inhibitor, in combination regimens in HIV-1 Infected Infants, Children & Adolescents

Investigator: Theodore Ruel, MD
Sponsor: Johns Hopkins University

Location(s): Uganda


The goal of this study is to determine a pediatric dose that approximates adult exposure.